High BRAF V600 Mutation Level Associated with Worse Outcome in Metastatic Melanoma Patients Receiving BRAF and MEK Inhibitors
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.High BRAF V600 mutation levels in melanoma tissue indicate a poorer prognosis for patients receiving BRAF and MEK inhibitors. This finding impacts understanding of treatment response in metastatic melanoma.
Area Of Science
- Oncology
- Molecular Biology
- Genetics
Background
- The prognostic significance of BRAF V600 mutation levels in metastatic melanoma treated with targeted therapies is not fully understood.
- BRAF and MEK inhibitors are standard treatments for BRAF V600-mutated melanoma.
Purpose Of The Study
- To investigate the association between BRAF V600 mutation level and clinical outcomes in metastatic melanoma patients treated with BRAF and MEK inhibitors.
- To determine if BRAF mutation level predicts progression-free survival (PFS), overall survival (OS), and response rates.
Main Methods
- Retrospective analysis of 58 metastatic melanoma patients with BRAF V600E/K mutations receiving BRAF/MEK inhibitors.
- BRAF V600 mutation level quantified as the ratio of BRAF V600 allele to tumoral cells.
- Multivariate analysis adjusted for age, sex, LDH, brain metastasis, and treatment line.
Main Results
- A BRAF V600 mutation level cut-off of 0.44 was identified.
- Higher BRAF V600 mutation levels (>0.44) were significantly associated with poor PFS and OS (p=0.02 for both).
- No association was observed between BRAF mutation level and 3-month response rate.
Conclusions
- High BRAF V600 mutation level in melanoma tissue is a significant predictor of poor prognosis in patients treated with BRAF and MEK inhibitors.
- BRAF mutation level may serve as a prognostic biomarker for guiding treatment decisions in metastatic melanoma.
- Further research is warranted to explore the mechanisms underlying this association.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...